Q1 2026 Recap: Dermatology News and Updates

In the first quarter of 2026, a variety of late-phase data, regulatory milestones, and emerging therapeutic strategies helped the dermatology landscape to leap ahead in its evolution. An array of US Food and Drug Administration (FDA) decisions expanded options for treatment across inflammatory and rare diseases, including the approvals of icotrokinra and secukinumab for psoriasis and pediatric hidradenitis suppurativa (HS), respectively.